At Bionano, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. Our team is not afraid to venture into uncharted territory to look for answers. We welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home.
Our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. Saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies.
At Bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality of life for all.
Our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. Saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies.
At Bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality of life for all.
Location: United States, California, San Diego
Employees: 201-500
Investors 1
| Date | Name | Website |
| 18.07.2021 | Ben Frankl... | sep.benfra... |
Mentions in press and media 5
| Date | Title | Description |
| 08.07.2024 | Bionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | $10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing o... |
| 08.07.2024 | Bionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an ag... |
| 05.07.2024 | Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | $10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has e... |
| 05.07.2024 | Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of an aggregate of 1... |
| 11.10.2023 | Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan | - |